FDA-cleared profile

Revolution Ascend Sliding

GE Hangwei Medical Systems Co., Ltd. · CT/CTA · FDA-cleared (510(k))

Authorized purpose: Revolution Ascend Sliding produces cross-sectional images by computer reconstruction of X-ray transmission data, including axial, cine, helical, cardiac, and gated acquisitions, with or without contrast. The FDA indication covers head, whole-body, cardiac, and vascular CT in patients of all ages and use for diagnosis and for planning, guiding, and monitoring therapy.

Clinical role
CT acquisition, reconstruction, display, image processing, and examination support under professional review.
Images and patients
CT/CTA · Head, whole body, heart, and vascular anatomy
Key limitation
Keep in mind: The exact protocol, contrast, patient, dose, reconstruction, accessories, and physician review determine applicability. The FDA indication is not a universal clinical-outcome or diagnostic-accuracy claim.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Revolution Ascend Sliding produces cross-sectional images by computer reconstruction of X-ray transmission data, including axial, cine, helical, cardiac, and gated acquisitions, with or without contrast. The FDA indication covers head, whole-body, cardiac, and vascular CT in patients of all ages and use for diagnosis and for planning, guiding, and monitoring therapy.
  • Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Head, whole body, heart, and vascular anatomy Input: X-ray transmission or projection data acquired under the labeled scanner, protocol, dose, contrast, patient, and reconstruction conditions.
  • Who uses it?Intended users: Qualified CT technologists and trained interpreting or treating physicians.
  • What does the software produce?Output: Cross-sectional CT images, reformats, spectral or attenuation information, and derived results for professional review.
  • What is its most important limitation?Key limitation: The exact protocol, contrast, patient, dose, reconstruction, accessories, and physician review determine applicability. The FDA indication is not a universal clinical-outcome or diagnostic-accuracy claim.

Clinical takeaway. Clinical role: Revolution Ascend Sliding produces cross-sectional images by computer reconstruction of X-ray transmission data, including axial, cine, helical, cardiac, and gated acquisitions, with or without contrast. The FDA indication covers head, whole-body, cardiac, and vascular CT in patients of all ages and use for diagnosis and for planning, guiding, and monitoring therapy.

Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports non-clinical testing only: compliance with AAMI/ANSI ES 60601-1, IEC60601-1 and associated standards, 21 CFR Subchapter J and NEMA XR standards; engineering design V&V and bench testing; and risk management, software verification and validation, and dose and image quality testing. Bench results showed the subject device performs equivalently to the predicate. It states the system can be fully tested on the engineering bench, so no additional clinical testing was required. Results are as reported in the FDA submission, not independent validation.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Revolution Ascend Sliding produces cross-sectional images by computer reconstruction of X-ray transmission data, including axial, cine, helical, cardiac, and gated acquisitions, with or without contrast. The FDA indication covers head, whole-body, cardiac, and vascular CT in patients of all ages and use for diagnosis and for planning, guiding, and monitoring therapy.
  • Exact FDA submission
  • Checked 2026-09-04
Workflow role
CT acquisition, reconstruction, display, image processing, and examination support under professional review.
  • Exact FDA submission
  • Checked 2026-09-04
Required input
X-ray transmission or projection data acquired under the labeled scanner, protocol, dose, contrast, patient, and reconstruction conditions.
  • Exact FDA submission
  • Checked 2026-09-04
Output and clinician action
Cross-sectional CT images, reformats, spectral or attenuation information, and derived results for professional review.
  • Exact FDA submission
  • Checked 2026-09-04
Care setting
Hospital or outpatient CT departments using the exact cleared scanner, accessories, protocols, and software.
  • Exact FDA submission
  • Checked 2026-09-04
Intended users
Qualified CT technologists and trained interpreting or treating physicians.
  • Exact FDA submission
  • Checked 2026-09-04
Limitations
The exact protocol, contrast, patient, dose, reconstruction, accessories, and physician review determine applicability. The FDA indication is not a universal clinical-outcome or diagnostic-accuracy claim.
  • Exact FDA submission
  • Checked 2026-09-04
Evidence summary
The exact FDA document reports non-clinical testing only: compliance with AAMI/ANSI ES 60601-1, IEC60601-1 and associated standards, 21 CFR Subchapter J and NEMA XR standards; engineering design V&V and bench testing; and risk management, software verification and validation, and dose and image quality testing. Bench results showed the subject device performs equivalently to the predicate. It states the system can be fully tested on the engineering bench, so no additional clinical testing was required. Results are as reported in the FDA submission, not independent validation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "The Revolution Ascend Sliding has completed testing and is in compliance with AAMI/ANSI ES 60601-1 and IEC60601-1 Ed. 3.2 and its associated collateral and particular standards, 21 CFR Subchapter J, and NEMA standards XR 25, XR 26, and XR 28." … "The device has successfully completed engineering design V &V and bench testing in support of substantial equivalence to the predicate device.". Read from the exact FDA decision document on 2026-11-14.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
The exact FDA document reports non-clinical testing only: compliance with AAMI/ANSI ES 60601-1, IEC60601-1 and associated standards, 21 CFR Subchapter J and NEMA XR standards; engineering design V&V and bench testing; and risk management, software verification and validation, and dose and image quality testing. Bench results showed the subject device performs equivalently to the predicate. It states the system can be fully tested on the engineering bench, so no additional clinical testing was required. Results are as reported in the FDA submission, not independent validation.
  • FDA source
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "The Revolution Ascend Sliding has completed testing and is in compliance with AAMI/ANSI ES 60601-1 and IEC60601-1 Ed. 3.2 and its associated collateral and particular standards, 21 CFR Subchapter J, and NEMA standards XR 25, XR 26, and XR 28." … "The device has successfully completed engineering design V &V and bench testing in support of substantial equivalence to the predicate device.". Read from the exact FDA decision document on 2026-11-14.

Reported sensitivity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-04

Sensitivity is not a product-wide endpoint for this system or software function. Compare only an exact endpoint, threshold, population, version, and source if later verified.

Reported specificity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-04

Specificity is not a product-wide endpoint for this system or software function. Compare only an exact endpoint, threshold, population, version, and source if later verified.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

K233749 FDA decision evidence for Revolution Ascend Sliding

  • DesignFDA 510(k) substantial-equivalence review of the exact submission, device description, indications, and verification or validation documentation.
  • PopulationHead, whole body, heart, and vascular anatomy
  • Scopeexact submission
  • Tested versionRevolution Ascend Sliding
  • IndependenceSponsor or vendor study

K233749

The FDA decision material is manufacturer-submitted regulatory evidence. It is not independent clinical validation, and local technical, clinical, privacy, security, and workflow acceptance remains necessary.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K233749 by exact native submission identifier. This does not exclude product-family, later, or adverse-event information.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-04

Exact-identifier review does not prove absence of all product-family safety signals.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

Reimbursement
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the product within the applicable imaging, procedural, surgical, or diagnostic service line and verify payer, site-of-service, and coding assumptions independently.
  • Service-level, not product-specific
  • Checked 2026-09-04

No product-specific code

No separate named-product payment identified in reviewed public material

Centers for Medicare & Medicaid Services · United States

Build a local total-cost and value model; do not infer reimbursement from FDA clearance or approval.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: X-ray transmission or projection data acquired under the labeled scanner, protocol, dose, contrast, patient, and reconstruction conditions.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-04 · FDA 510(k) decision material K233749: Revolution Ascend Sliding

  2. Routing

    Unresolved route: Not established for the exact route.

    Scope: Exact FDA submission. The exact FDA decision material does not establish a complete integration contract. Confirm DICOM, worklist, identity, interfaces, exports, routing, audit behavior, archive, and downtime locally.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-04 ·

  3. AI processing

    Unresolved route: Not established for the exact route.

    Scope: Exact FDA submission. The exact FDA decision material does not establish the complete deployment topology, hosting responsibility, availability, upgrade path, or service contract.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-04 ·

  4. Returned objects

    Source context, not route validation: Cross-sectional CT images, reformats, spectral or attenuation information, and derived results for professional review.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-04 · FDA 510(k) decision material K233749: Revolution Ascend Sliding

  5. Viewer/worklist/report

    Unresolved route: Cross-sectional CT images, reformats, spectral or attenuation information, and derived results for professional review.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-04 · FDA 510(k) decision material K233749: Revolution Ascend Sliding

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Security
GE HealthCare's Product Security Portal is described as a credentialed global portal giving customers security updates, vulnerability status and required actions for GE HealthCare products potentially impacted by critical vulnerabilities, plus historical patch views; GE HealthCare references its Cybersecurity Risk Management System and publishes a Coordinated Vulnerability Disclosure Statement for reporting vulnerabilities in GE HealthCare products.
  • Vendor-wide
  • Checked 2026-10-26

Vendor statement, not an attestation. Identity bridge: GE HealthCare's own offices page on gehealthcare.com names Ge Hangwei Medical Systems Co., Ltd (Beijing). Corporate program statement; portal content is credentialed; exact-release scope is not established.

Training
Only qualified ct technologists and trained interpreting or treating physicians should operate or interpret this product. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
  • Exact FDA submission
  • Checked 2026-09-04
Monitoring
Monitor by exact hardware, software, model, algorithm, reconstruction, or configuration version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: The exact protocol, contrast, patient, dose, reconstruction, accessories, and physician review determine applicability. The FDA indication is not a universal clinical-outcome or diagnostic-accuracy claim.
  • Exact FDA submission
  • Checked 2026-09-04

Release and scope verification

Map installed model, build, options, population, anatomy, inputs, outputs, and enabled functions to K233749 before acceptance. Later family features are not evidence for this exact submission.

exact submission · checked 2026-09-04

Interoperability acceptance

The exact FDA material does not establish a complete interoperability contract. Establish and test supported input, output, identity, routing, archive, and downtime behavior locally.

exact submission · checked 2026-09-04

Deployment and security qualification

The exact FDA material does not establish hosting, deployment topology, availability, upgrade path, or service responsibility. Obtain site-specific evidence before procurement.

exact submission · checked 2026-09-04

Clinical acceptance

Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. The exact protocol, contrast, patient, dose, reconstruction, accessories, and physician review determine applicability. The FDA indication is not a universal clinical-outcome or diagnostic-accuracy claim.

exact submission · checked 2026-09-04

Define stop-use, escalation, rollback, and revalidation triggers before production use.

Economic evaluation

Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs. No exact-product price was found.

product family · checked 2026-09-04

Lifecycle monitoring

Monitor by exact hardware, software, model, algorithm, reconstruction, or configuration version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: The exact protocol, contrast, patient, dose, reconstruction, accessories, and physician review determine applicability. The FDA indication is not a universal clinical-outcome or diagnostic-accuracy claim.

exact submission · checked 2026-09-04

Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K233749
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
CT/CTA
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Anatomy
Head, whole body, heart, and vascular anatomy
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2024-02-22
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-20Last searched
33Fields reviewed
12Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, fda decision material, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission

    No public list price for the exact cleared or approved configuration was found. Obtain a written quote separating hardware or license basis, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Deployment: Not publicly available - checked 2026-09-04 - Exact FDA submission

    The exact FDA decision material does not establish the complete deployment topology, hosting responsibility, availability, upgrade path, or service contract.

  • Integration: Not publicly available - checked 2026-09-04 - Exact FDA submission

    The exact FDA decision material does not establish a complete integration contract. Confirm DICOM, worklist, identity, interfaces, exports, routing, audit behavior, archive, and downtime locally.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed

7 sources - 3 history items

Source ledger

  1. FDA 510(k) decision material K233749: Revolution Ascend Sliding

    U.S. Food and Drug Administration - Published 2024-02-22 - Accessed 2026-09-04

    Scope: identity, purpose, clinicalUse, modality, anatomy, intendedUsers, careSetting, workflowRole, input, output, limitations, evidenceSummary

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  4. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  5. Medicare Coverage Database

    Centers for Medicare & Medicaid Services - Accessed 2026-09-01

    Scope: coverage, codingContext

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. GE HealthCare: Product Security (portal and Cybersecurity Risk Management System)

    GE HealthCare - Accessed 2026-10-26

    Scope: security

Research history

  1. K233749 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K242403

Aquilion ONE (TSX-308A/3) V1.5

Canon Medical Systems Corporation

Authorized purpose: Aquilion ONE (TSX-308A/3) V1.5 acquires and displays cross-sectional volumes of the whole body, including the head, with the capability to image whole organs in a single rotation. The FDA material describes specialized studies with indicated software or hardware, FIRST reconstruction, AiCE noise reduction, spectral imaging, and PIQE high-resolution reconstruction for labeled applications.

Modality
CT/CTA
Anatomy
Head, whole body, heart, and vascular anatomy
Decision
2024-12-23
FDA-cleared K253786

syngo.CT Coronary Cockpit

Siemens Medical Solutions USA, Inc.

Authorized purpose: An extension for syngo.via that assists trained physicians with automated and semi-automated analysis, visualization and reporting of cardiac CT angiography volume datasets for coronary-lesion evaluation, documentation, follow-up and treatment planning.

Modality
CT/CTA
Anatomy
Heart/Cardiovascular
Decision
2026-06-25
FDA-cleared K260324

Vitrea CT Transcatheter Aortic Valve Replacement (TAVR) Planning

Canon Medical Informatics, Inc.

Authorized purpose: Assist assessment and pre-operative planning and post-operative evaluation of transcatheter aortic valve replacement procedures.

Modality
CT/CTA
Anatomy
Aortic valve/root, LVOT and ventricles, coronary ostia, cardiac structures, and iliac/femoral/abdominal aortic access vessels
Decision
2026-05-22

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history